HeyJaredMichael Erman
- Indexed articles, last 90 days
- 3
- Latest publication
- Aug 19, 2026
- Outlet visibility, for Theglobeandmail
- Top 10K sites
- Earliest in this view
- Jul 15, 2026
Latest articles
Moderna shares surge as melanoma vaccine with Merck succeeds in large trial (opens the original)
Read excerpt
Moderna MRNA-Q and Merck MRK-N said on Wednesday that a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna’s shares surging as much as 160 per cent. The companies tested the vaccine together with Merck’s immunotherapy drug Keytruda, a widely used melanoma treatment. Thousands of patients who have undergone surgery to remove high-risk melanoma tumours could benefit as so
Merck’s sales rise more than expected, lifts full-year outlook (opens the original)
Read excerpt
Merck MRK-N reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue forecast on the strength of its top-selling cancer treatment Keytruda. The U.S. drugmaker reported quarterly revenue of US$16.61-billion, up 5 per cent from a year earlier and above analysts’ average estimate of US$16.36-billion, according to LSEG data. Merck reported a loss for the quarter due to a US$5.7-billion charge from its acquisition of cancer drug developer Terns Pharmaceuticals. T
J&J tops estimates on strong medicine sales, raises full-year outlook (opens the original)
Read excerpt
Johnson & Johnson JNJ-N beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster Darzalex more than offset erosion from older products and a drop in sales for heart pumps it picked up in its 2022 acquisition of Abiomed. J&J also increased its full-year sales and profit forecast. The healthcare conglomerate reported second-quarter sales of US$25.31-billion, up 6.6 per cent from a year earlier and above analys
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 10K sites
For Theglobeandmail, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.